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Abstract
Objective To assess experiences related to antidepressant
use reported to an internet-based medicine reporting system
and to compare the nature of the side effects reported by
patients with those reported by health care professionals
(HCPs).
Methods All reports submitted from May 2004 to May
2005 to an internet-based medicine reporting system in The
Netherlands related to the use of antidepressants were
analysed. Spontaneous reports of adverse drug reactions on
antidepressants from HCPs received by The Netherlands
Pharmacovigilance Centre Lareb from May 2004 to May
2005 were included for comparison.
Results Of the 2232 individuals who submitted a report to
the internet-based medicine reporting system, 258 submit-
ted a report on antidepressants. Of these, 92 individuals
(36%) reported on effectiveness, 40 (16%) of whom
reported on ineffectiveness, and 217 (84%) submitted a
report on side effects, with 202 (78%) reporting a total of
630 side effects that were experienced as negative. Fourteen
individuals (5%) reported a practical issue and four (2%)
reported a reimbursement issue. Of all 630 side effects
reported, 48% resulted in the patient discontinuing the
antidepressant therapy; of these 29% did not inform their
HCP. Of all the side effects reported, 52% were perceived
as “very negative”. In comparison to the side effects
reported by HCPs, patients more often reported apathy,
excessive sweating, ineffectiveness, somnolence, insomnia,
sexual problems and weight increase.
Conclusion Patients report the ineffectiveness and side
effects of antidepressant therapy as negative and leading
to discontinuation of the therapy. Patients and HCPs differ
in the nature of the reported side effects. Patient experi-
ences should be included in the evaluation of antidepressant
treatment in clinical practice.
Keywords Adverseevents.Antidepressants.
Discontinuation.Patientreporting
Introduction
Non-adherence to prescribed medication regimens is a
persistent problem in the treatment of depression with
antidepressants. Premature discontinuation, dosing lapses
and partial non-adherence often occur [1–3]. The illness
itself as well as physician-, patient- and treatment-related
factors have been suggested to contribute to antidepressant
non-adherence, but the ability of health care professionals
(HCP) to predict who discontinues medication remains
poor [4–6]. Earlier studies provide scant information on
how patients in clinical practice perceive their treatment
with antidepressants, thus insight and an understanding of
the patients’ perspectives on non-adherence and discontin-
uation are limited. Side effects and ineffectiveness are the
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sant therapy [7, 8]. However, the information available on
side effects is mostly based on controlled clinical trials,
which standardly do not evaluate how bothersome side
effects are to the individual patient. Moreover, both the side
effects and the effectiveness of the antidepressant therapy
observed in clinical trials may not reflect the experiences of
the patients in real world settings. Many interventions have
been developed to improve adherence to antidepressants,
but to date these have failed to demonstrate a clear benefit
[9, 10]. Treatment non-adherence remains one of the least
understood health-related behaviours. Information received
directly from the patient may improve our understanding of
the relative importance of antidepressant treatment issues
and, consequently, help to explain patients’ behaviour
towards antidepressant use.
Reporting systems have shown to be a useful tool in
collecting experiences and identifying issues related to the
daily use of medicines [11]. In 2004, an internet-based
medicine reporting system was established in The Nether-
lands where users of medicines are able to report all types
of experiences with medicines – side effects as well as
experiences with effectiveness and practical and reimburse-
ment issues. We extracted data from this medicine reporting
system in order to (1) assess the type of experiences related
to antidepressant use reported by patients, (2) assess the
relevance of these experiences and (3) compare the nature
of the suspected side effects reported by patients with those
reported by HCPs.
Methods
Setting
Reports were obtained from an internet-based medicine
reporting system launched on 11 May 2004 in The
Netherlands. This reporting system was initiated by DGV,
The Dutch Institute for the Proper Use of Medicine, the
Science Shop for Medicines and patient and consumer
organisations. Individuals are able to report their experi-
ences with medicines anonymously by completing a report
form downloaded by accessing a website (http://www.
meldpuntmedicijnen.nl). Users of the medicine themselves
as well as their relatives, acquaintances or (professional)
carers, can report an experience. All reports submitted
between 11 May 2004 and 13 May 2005 related to the use
of antidepressants were reviewed for the clarity and
completeness of the description of the experience and
checked for multiple reports from the same IP-address. One
duplicate report had to be excluded. All other reports were
included in the study. The data were stored in an Access
database.
Report form
The report form contained items which requested informa-
tion on age, gender, type of medicine used, nature of the
experience, a description of the experience and the
relevance of the experience. Individuals filling in the report
had to indicate whether the experience was related to either
effectiveness, a side effect, a practical issue (e.g. difficulties
with swallowing tablets) or a reimbursement issue. More
than one experience related to the same drug could be
submitted. Experiences related to effectiveness had to be
further specified by the individual by selecting one of the
following categories: ineffectiveness, a positive effect or a
different type of effect (e.g. drug interactions). Experiences
related to side effects had to be further specified by
selecting one of the following categories: negative side
effects, positive side effects (e.g. less side effects as
compared with previous medication) or the absence of side
effects. Relevance of the experience was assessed by asking
the individual filling in the report to indicate both the
impact of the experience on a 5-point scale (ranging from
very negative to very positive) and whether the experience
caused a change in antidepressant use. To specify the
change in antidepressant use, those reporting had to select
one of the following categories: discontinuation, switching
to other treatment, adjustment of dosage or administration,
any other action taken or no action taken. In the case of
discontinuation of the antidepressant, the report also asked
whether the HCP has been informed.
Side effects
All reported side effects (including experiences on ineffec-
tiveness) were coded by one of the authors (SvdW) and
checked by a second author (EvG), using preferred terms of
the World Health Organisation Adverse Reaction Terminol-
ogy (WHO-ART) [12]. Preferred terms were combined into
groups of similar side effects. Spontaneous reports of
adverse drug reactions on antidepressants received from
HCPs from May 2004 to May 2005 were included for
comparison. These reports were received by The Netherlands
Pharmacovigilance Centre Lareb either on paper forms or
electronically via http://www.lareb.nl. Coding and assess-
ment were carried out by qualified assessors from Lareb [13].
Data analysis
The relevance of the side effects was assessed by com-
paring the impact of the (grouped) side effects as a
proportion of the side effects that were perceived as “very
negative”. Relevance was also assessed by comparing the
proportion of the side effects that caused discontinuation of
initial antidepressant use, including the categories “discon-
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and discontinuation proportions of the different groups of
side effects were compared using the chi-square test.
For the comparison between patients and HCPs, the
groups of side effects were compared and expressed as an
Odds Ratio (OR) and 95% confidence interval (CI). The 15
most frequently reported (groups of) side effects by patients
as well as the 15 most frequently reported (groups of) side
effects by HCPs were included in the analysis.
Results
Characteristics
In total 2232 individuals submitted a report to the medicine
reporting system during the study period, of whom 258
(12%) submitted a report on antidepressants. Of these 258
individuals, 248 (96%) reported for themselves and ten
reported for a relative or acquaintance.
The mean (±SD) age of the of the antidepressant users
was 42.8 (±13.5) years and 72% were female. The majority
of those reporting on antidepressants (63%) were reporting
on a serotonin-reuptake inhibitor (SSRI); 12% were report-
ing on a tricyclic antidepressant (TCA) and 25% on another
type of antidepressant. The antidepressants most frequently
reported on were paroxetine (35% of total), venlafaxine
(15%), citalopram (10%) and mirtazapine (8%). The use of
a benzodiazepine as a concomitant drug was reported by
19% of those reporting on antidepressant use.
Nature of experiences
The 258 individuals reporting onantidepressantuse described
327 experiences. Table 1 shows the nature of the experiences
described. Ninety-two individuals (36%) described an
experience with effectiveness, of whom 40 (16%) described
an experience with ineffectiveness. Four individuals claimed
generic substitution as the reason for ineffectiveness, and 45
(17%) reported a positive experience with the effectiveness
of an antidepressant. “Other type of effects” in terms of
effectiveness that were submitted by seven (3%) individuals
included experiences on suspected drug interactions.
In total, 217 of the 258 individuals (84%) reporting on
antidepressantuse submitteda reportonsideeffects.Ofthese,
202 (78%) described a total of 630 side effects that were
experienced as negative. The number of reported side effects
ranged from 1 to 11 per reporter experiencing a negative side
effect. Twelve individuals (5%) reported that they had not
experienced any side effect at all, and three (1%) submitted a
positive experience with side effects, reporting that their
current antidepressant therapy caused fewer side effects than
their previous medication.
Fourteen individuals (5%) reported a practical issue
(such as problems with swallowing tablets or bad taste),
and four (2%) reported a reimbursement or availability
issue (receiving treatment for a relative short duration).
Box 1 shows a number of the reported experiences.
Relevance of side effects
Table 2 shows the relevance, impact and discontinuation
rates of the most frequently reported side effects. Of all side
effects, 48% resulted in discontinuation of the initial
antidepressant therapy. The proportion of side effects that
caused discontinuation of the initial antidepressant did not
differ significantly between the different side effects. Of
those individuals who simultaneously reported an experience
on side effects and one on ineffectiveness, 59% (17/29) re-
ported that their experience resulted in discontinuation of the
initial antidepressant therapy. Of all individuals who reported
discontinuation of therapy, 29% did not inform their HCP.
Of all side effects, 52% were perceived as “very negative”.
The impact of the side effects differed almost significantly
between the groups of side effects (p=0.052), with headache,
dizziness and fainting perceived as most negative.
Side effects compared between patients and HCPs
Table 3 presents those side effects most frequently reported
by patients and HCPs. Patients and HCPs differed in the
Table 1 Nature of the reported experiences related to antidepressant use
reportedtoamedicine reportingsystem(http://www.meldpuntmedicijnen.nl)
a
Issue Proportion of total
number of
individuals (n=
258) reporting on
antidepressant use
Nature of
issue
Proportion
individuals
reporting on a
specific issue
Effectiveness 36% (n=92) Ineffectiveness 16% (n=40)
Positive effect 17% (n=45)
Other 3% (n=7)
Side effects 84% (n=217) Negative side
effect
78% (n=202)
Positive side
effect
1% (n=3)
Absence of
side effect
5% (n=12)
Practical issues 5% (n=14)
Reimbursement
and
availability
issues
2% (n=4)
aA total of 258 reporters submitted 327 experiences. The reported
experiences are expressed as a percentage of the total number of
individuals submitting reports
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patients reported significantly more events such as apathy,
excessive sweating, ineffectiveness, discontinuation symp-
toms, somnolence, insomnia, sexual problems and weight
increase. HCPs reported significantly more rash, pruritis,
laboratory abnormalities, muscle and joint complaints,
congenital disorders, eye disorders, extrapyramidal disor-
ders and menstrual disorders than patients.
Discussion
Both side effects and a lack of effectiveness appear to be
important treatment issues for patients who reported on
antidepressants in our study. Most of the individuals
reporting on antidepressant use described one or more side
effects, of which the most frequent were weight increase,
sexual problems, somnolence, insomnia and apathy. Inef-
fectiveness was also reported by a considerable number of
individuals. Ineffectiveness is not often reported in litera-
ture as an adverse effect of treatment [14]. However, our
study reveals that it is a relevant issue for patients during
antidepressant therapy. The fact that side effects tend to
occur before the therapeutic effect of the antidepressant is
perceived may play an important part in explaining early
discontinuation of the therapy. Ineffectiveness should
therefore receive attention from HCPs in order to prevent
early discontinuation of antidepressants.
One of the unique features of this medicine reporting
system is the possibility to gather information on the
relevance of the experiences – that is the impact of the
experience and the change in initial treatment. Overall, half
of the experiences were perceived as very negative.
Experience of one or more bothersome side effects means
an individual is threefold more likely to stop taking
antidepressants [7]. Our results show that one half of the
side effects resulted in discontinuation of the initial
antidepressant therapy. Moreover, of all those individuals
who reported discontinuation of therapy, 29% did not even
inform their HCP. This supports the concept that this
medicine reporting system provides data of which HCPs are
often not aware, but which are of crucial importance to any
understanding of patients’ behaviour related to the use of
antidepressants.
Patients and HCPs differed in the nature of the side
effects reported. Patients were found to report more
frequently those events which may be less tangible and
visible to HCPs, such as sleeping problems and apathy. In
addition, HCPs may consider symptoms reported by
patients with psychiatric disorders as a symptom of the
disease rather than as one related to the medication. Other
notable differences between patients and HCPs in terms of
the frequency of reported side effects were those of weight
increase, sexual problems, discontinuation symptoms and
excessive sweating. The differences in the nature of the
reported side effects show that patients and HCPs differ in
w h i c ht y p eo fs i d ee f f e c t sc a nb ec o n s i d e r e dt ob e
bothersome and/or relevant to report. The burden of side
effects is clearly underestimated by HCPs [15]. Although
HCPs are knowledgeable on the side effects related to SSRI
use, they underestimate the frequency of these side effects
and how bothersome they are to patients [16]. In addition,
HCPs may be reticent in reporting a side effect to a
reporting system. More than patients, HCPs evaluate the
side effect reported by the patient according to perceived
relevance and causality related to the medication. Side
effects which are considered by the HCP as well-known or
not related to the medication consequently get lost to the
health care system [17].
Patient reporting is not yet widely accepted, and the
number of systems collecting experiences from patients is
still limited. In the UK, the Prescription-Event Monitoring
(PEM) system seeks to identify adverse events recorded
following the use of newly marketed drugs selected for
monitoring on the first 20,000–50,000 patients given the
new drug [18]. Since the middle of 2003, the Danish
Medicines Agency and the Netherlands Pharmacovigilance
Centre Lareb also accept reports on adverse drug reactions
from patients [19]. In Sweden, the KILEN Consumer
Institute for Medicines and Health started a consumer data-
base in 1997 that collects experiences related mainly to
Table 2 Relevance of the most frequently reported side effects related
to antidepressant use
Side effect Number of
reported
experiences
(n)
Impact (%
perceived
as “very
negative”)
Discontinuation of
antidepressant
use (%)
Sleep disorder 68 47 50
Somnolence,
drowsiness, fatigue
39 51 59
Insomnia,
sleeplessness
29 41 38
Weight increase 48 46 56
Sexual problems 43 44 33
Discontinuation
symptoms
40 43 50
Ineffectiveness 40 35 53
Apathy 28 46 54
Excessive sweating 23 43 39
Nausea, gagging 23 39 30
Dizziness, fainting 23 65 35
Headache 22 68 50
Dry mouth 18 50 61
Suicidal attempt,
thought or tendency
a
97 8 7 8
aSuicidal attempts, thoughts or tendency is also included, although the
number of reported experiences was less than 15.
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pressant use [19]. However, these systems focus only on
adverse events, while other aspects of medicine use, in-
cluding experiences on ineffectiveness, practical and reim-
bursement issues, have also been shown to be relevant to
patients.
A limitation of this internet-based reporting system is
that the reporters are anonymous and, therefore, further
contact and feedback are not possible. Consequently, a
thorough assessment of causality between the side effect
and the antidepressant was not always possible. The
Netherlands Pharmacovigilance Centre Lareb, on the other
hand, whose primary aim is the early detection of new
adverse drug reactions, has the facilities to request further
medical information by contacting the patient and/or his/her
HCP [20]. However, we believe this does not detract from
our conclusion. The individuals reporting through the
internet-based reporting system proved to be capable of
providing clear descriptions of their experiences and of
balancing the benefits and burden of treatment. The patient
experiences provide important information on how patients
in clinical practice perceive treatment with antidepressants.
Such patients experience sleep disorders, weight increase,
sexual problems, apathy and ineffectiveness as events
which have a negative impact and which frequently lead
to discontinuation of the antidepressant therapy. Because
adherence decisions are mostly a rational balance of per-
ceived benefits versus burden [21], an assessment of patient
experiences may improve the understanding of patients’
behaviour towards antidepressant use. This information can
Table 3 Reported side effects on antidepressants by patients compared with reported side effects on antidepressants by health care professionals
(HCPs)
Side effect Number of reported
side effects by
patients
Percentage of total
number of side
effects
(n=670)
Number of
reported
side effects
by HCPs
Percentage of total
number
of side effects
(n=471)
Odds ratio
(95% CI)
a
Top 15 most frequently reported side effects by patients
Weight increase 48 7.2 6 1.3 5.98 (2.54–14.09)
Sexual problems 43 6.4 6 1.3 5.31 (2.24–12.59)
Discontinuation symptoms 40 6.0 3 0.6 14.14 (4.35–45.93)
Ineffectiveness 40 6.0 3 0.6 14.14 (4.35–45.93)
Somnolence, drowsiness, fatigue 39 5.8 8 1.7 3.58 (1.66–7.73)
Insomnia, sleeplessness 29 4.3 4 0.8 5.28 (1.84–15.13)
Apathy 28 4.2 0 0 –
Excessive sweating 23 3.4 0 0 –
Nausea, gagging
b 23 3.4 8 1.7 2.05 (0.91–4.64)
Dizziness, fainting
b 23 3.4 8 1.7 2.05 (0.91–4.64)
Headache
b 22 3.3 11 2.3 1.42 (0.68–2.96)
Dry mouth 18 2.7 3 0.6 4.31 (1.26–14.71)
Abdominal pain 14 2.1 3 0.6 3.33 (0.95–11.65)
Anxiety 13 1.9 2 0.4 4.64 (1.04–20.66)
Depressed mood 11 1.6 3 0.6 2.60 (0.72–9.39)
Top 15 most frequently reported side effects by HCPs
Rash, urticaria and pruritis 3 0.4 23 4.9 0.09 (0.03–0.29)
Laboratory abnormalities 0 0 22 4.7 –
Muscle and joint complaints 3 0.4 20 4.2 0.10 (0.03–0.34)
Congenital disorders 0 0 15 3.2 –
Eye and vision disorders 6 0.9 15 3.2 0.27 (0.11–0.71)
Paraesthesia 8 1.2 12 2.5 0.46 (0.19–1.14)
Headache
b 22 3.3 11 2.3 1.42 (0.68–2.96)
Extrapyramidal disorders, Parkinsonism 1 0.1 10 2.1 0.07 (0.01–0.54)
Menstrual disorders, vaginal bleedings 3 0.4 10 2.1 0.21 (0.06–0.76)
Heart rhythm problems 7 1.0 10 2.1 0.49 (0.18–1.29)
Convulsions, epilepsy 0 0 9 1.9 –
Drug substitution problems 7 1.0 8 1.7 0.61 (0.22–1.70)
Serotonin syndrome 0 0 8 1.7 –
Nausea, gagging
b 23 3.4 8 1.7 2.06 (0.91–4.64)
Dizziness, fainting
b 23 3.4 8 1.7 2.06 (0.91–4.64)
95% CI, 95% confidence interval
aOR>1: Patients were more likely to report the side effect than the HCPs; OR<1: HCPs were more likely to report the side effect than the patients
bSide effects that appear in both the patients’ and HCPs’ list
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enhancing strategies that may lead to optimisation of
antidepressant treatment from the perspective of both HCPs
and patients.
Appendix
Box 1: Examples of experiences reported to the patient
reporting system
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